Wednesday, 22 May 2019

You are here

Complementary Therapies in Psoriasis

A systematic review in Archives of Dermatology suggests that among complementary and alternative medicine (CAM) therapies, the most effective are indigo naturalis, curcumin, dietary modification, meditation, and acupuncture.

It is estimated that  nearly half of patients with psoriasis report they use CAM, although their benefits are unclear in psoriasis.

A review of 57 trials and 3 meta-analyses found that, compared with placebo:

  • topical indigo naturalis showed significant improvements in the treatment of psoriasis
  • curcumin found statistically and clinically significant improvements in psoriasis plaques
  • fish oil treatment showed no significant improvement in psoriasis
  • Meditation and guided imagery therapies showed modest efficacy in treatment of psoriasis
  • acupuncture showed significant improvement in psoriasis 

Despite widespread use, many studies and findings were negative. Nonetheless, a few CAM therapies can be supported by the evidence.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed.